drugset / Trial / NCT07207395
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.
Timeline
- Start
- 2025-04-29
- Primary completion
- 2027-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JBI-802 | Small molecule | 10 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |